WHAT IS ADJUVANT THERAPY?

Adjuvant therapy is additional treatment administered after radical cystectomy for carefully selected patients who have a high risk of bladder cancer recurrence. Its goal is to eliminate microscopic cancer cells that may remain after surgery and reduce the risk of disease recurrence. According to the 2026 European Association of Urology (EAU) Guidelines, adjuvant cisplatin-based chemotherapy or adjuvant immunotherapy may be considered based on pathological findings, lymph node status, tumor stage, previous treatments, and the patient’s overall clinical condition.

TABLE OF CONTENTS

What is adjuvant therapy?

Who may benefit from adjuvant therapy?

Which treatments are available?

What is adjuvant chemotherapy?

What is adjuvant immunotherapy?

When is treatment started?

The EAU 2026 key message for patients

Multidisciplinary treatment planning with Assoc. Prof. Dr. Serdar Yalçın

Frequently Asked Questions

WHAT IS ADJUVANT THERAPY?

Adjuvant therapy refers to additional treatment given after cancer surgery.

Its purpose is to eliminate microscopic cancer cells that may remain in the body after surgery and reduce the likelihood of cancer recurrence.

WHO MAY BENEFIT FROM ADJUVANT THERAPY?

Adjuvant therapy is not necessary for every patient.

According to the 2026 European Association of Urology (EAU) Guidelines, it may be considered for selected patients with:

• Advanced pathological stage

• Positive lymph nodes

• High risk of disease recurrence

• No previous neoadjuvant chemotherapy or clinical features suggesting potential benefit from additional treatment

Treatment decisions should always be made within a multidisciplinary tumor board.

WHICH TREATMENTS ARE AVAILABLE?

Depending on the patient’s individual clinical characteristics, treatment options may include:

• Cisplatin-based adjuvant chemotherapy

• Adjuvant immunotherapy

The most appropriate treatment should always be individualized.

WHAT IS ADJUVANT CHEMOTHERAPY?

Adjuvant chemotherapy is systemic anti-cancer treatment administered after surgery.

It is primarily considered for eligible patients who did not receive neoadjuvant chemotherapy before radical cystectomy and who have high-risk pathological features.

WHAT IS ADJUVANT IMMUNOTHERAPY?

Adjuvant immunotherapy uses immune checkpoint inhibitors to enhance the body’s immune response against remaining cancer cells.

According to current international guidelines, it represents an important treatment option for selected patients with high-risk urothelial carcinoma following radical surgery.

WHEN IS TREATMENT STARTED?

Treatment is usually initiated after adequate postoperative recovery.

The final decision depends on surgical recovery, pathological findings, kidney function, previous treatments, and the patient’s overall health.

THE EAU 2026 KEY MESSAGE FOR PATIENTS

According to the 2026 European Association of Urology (EAU) Guidelines, adjuvant therapy should not be routinely administered to every patient.

Treatment decisions should be individualized based on pathological stage, lymph node involvement, previous treatments, overall health, and multidisciplinary evaluation.

MULTIDISCIPLINARY TREATMENT PLANNING WITH ASSOC. PROF. DR. SERDAR YALÇIN

Assoc. Prof. Dr. Serdar Yalçın evaluates patients after radical cystectomy in Bodrum, Türkiye, together with specialists in medical oncology, radiology, and pathology.

Detailed pathological findings are reviewed carefully, and options including adjuvant chemotherapy, adjuvant immunotherapy, or active surveillance are discussed according to the latest European Association of Urology (EAU) Guidelines.

In addition to patients from Bodrum and the Muğla region, individuals from across Türkiye and abroad seek consultation for second opinions and comprehensive postoperative bladder cancer treatment planning.

Patients frequently highlight detailed communication, evidence-based recommendations, multidisciplinary decision-making, individualized treatment planning, and continuous support throughout recovery.

CONCLUSION

Adjuvant therapy is an important treatment option for carefully selected patients with high-risk bladder cancer following radical cystectomy. Individualized treatment decisions based on current international guidelines and multidisciplinary evaluation provide the best opportunity to reduce recurrence and improve long-term oncological outcomes.

FREQUENTLY ASKED QUESTIONS

Will every patient need chemotherapy after radical cystectomy?

No. The decision depends on the final pathology report and the patient’s individual risk profile.

Can immunotherapy replace chemotherapy?

Not always. The most appropriate treatment depends on pathological findings, previous therapy, kidney function, and other clinical factors.

How soon after surgery is adjuvant therapy started?

Treatment is generally initiated after adequate postoperative recovery and completion of the pathological evaluation.

(Bu içerik Değişik Platformlar taranarak alıntılanmıştır)